First aim: PARIS study The main aim of the current study is to determine the association between abdominal aortic aneurysm (AAA) progression and the evolution of proteases and cytokines levels.To achieve this aim, we will prospectively collect blood, aortic tissue, patient data, and imaging data. Aortic tissue will only be obtained when patients undergo conventional open repair. The other biomaterials will be collected during regular patient follow-up visits, with a maximum frequency of once per year. Second aim: Pearl AAA biobank For future research purposes, a new biobanking infrastructure will be created to collect and store additional blood and urine samples in a biobank. This biobank will be embedded within the infrastructure of the 'Parelsnoer Institute' (PSI) and will be called Pearl AAA. The Pearl AAA will be established in the extension of the PARIS study
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
AAA growth
Timeframe: Up to 10 years of follow-up
AAA rupture
Timeframe: Up to 10 years of follow-up
Death
Timeframe: Up to 10 years of follow-up
Evolution of serum levels of proteases
Timeframe: a maximum of 1 measurement annually up to 10 years of follow-up
Evolution of serum levels of cytokines
Timeframe: a maximum of 1 measurement annually up to 10 years of follow-up
Protease levels in aortic tissue
Timeframe: If open AAA repair is performed and aortic tissue is collected, protease levels will then be measured. This is a one-time measurement.
Cytokine levels in aortic tissue
Timeframe: If open AAA repair is performed and aortic tissue is collected, cytokine levels will then be measured. This is a one-time measurement.